CCO Oncology Podcast

Clinical Considerations for RET Fusion–Positive NSCLC

Episode Summary

Listen to lung cancer experts Joshua Bauml, MD, a molecular oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, including testing for <i>RET</i> fusions, using new selective RET inhibitors in these patients, and the importance of interdisciplinary communication.

Episode Notes

In this podcast episode, listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, with topics including:

• Optimal testing for RET fusions
• DNA NGS vs RNA NGS
• Molecular testing workflows
• Using new selective RET inhibitors to treat patients with RET fusion–positive NSCLC
• Common toxicities with new selective RET inhibitors
• Interdisciplinary communication between medical oncologists and pathologists

Presenters:
Dara L. Aisner, MD, PhD
Associate Professor
Department of Pathology
Director, Molecular Pathology
University of Colorado
Aurora, Colorado

Joshua Bauml, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Link to full program, including associated downloadable slidesets:
https://bit.ly/2Fsq9Wv